| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 278,633 | 264,566 | 244,317 | 250,401 |
| Cost of product sales | 21,647 | 20,734 | 20,392 | 18,857 |
| Research and development | 87,829 | 77,951 | 78,265 | 66,606 |
| Selling, general and administrative | 133,401 | 133,507 | 126,370 | 133,294 |
| Total operating expenses | 242,877 | 232,192 | 225,027 | 218,757 |
| Income from operations | 35,756 | 32,374 | 19,290 | 31,644 |
| Interest income, net | 8,246 | 7,243 | 7,901 | 6,586 |
| Other income | 593 | 594 | 588 | 576 |
| Income before income taxes | 44,595 | 40,211 | 27,779 | 38,806 |
| Income tax expense (benefit) | -27,184 | 13,545 | 8,792 | 6,041 |
| Net loss | 71,779 | 26,666 | 18,987 | 32,765 |
| Diluted | 0.42 | 0.16 | 0.11 | 0.2 |
| Earnings per share, basic, total | 0.43 | 0.16 | 0.11 | 0.2 |
| Weighted average common shares outstanding, basic | 168,836,000 | 167,827,000 | 166,808,000 | 165,974,000 |
| Weighted average common shares outstanding, diluted | 170,650,000 | 168,681,000 | 167,668,000 | 166,178,000 |
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)